FDA pursues shutdown recovery

Share this article:

Merck and Stallergenes are reclaiming their places in front of the FDA's advisory committees. The 16-day government shutdown scuttled the reviews of their allergy medications Grastek (Merck) and Oralair (Stallergenes), since they were not covered by the user fees that allowed the regulator to review and approve drugs while Congress froze government funding during the fight over healthcare reform.

The review committees are set for Dec. 12 (Merck) and Dec. 11 (Stallergenes).

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M inVISION